Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Cirrus Logic enters its November earnings window with a notable divergence: the stock is down 6% on the week while shorts are quietly adding exposure, yet the lending market remains extraordinarily loose, suggesting the selling pressure is coming from somewhere other than a crowded short book.
The short positioning tells a specific story. Short interest has climbed to 6.7% of free float, up roughly 3% on the day and about 1% on the week, after running lower through September from a peak near 7.9% of float in mid-September. The rebuild is modest, not aggressive. What makes the lending picture genuinely uninteresting from a squeeze perspective is the availability reading: over 1,300% of outstanding short interest is available to borrow, meaning there are more than thirteen shares available to lend for every one already shorted. Cost to borrow is 0.42%, down 8% on the week and near multi-month lows. This is not a stock where borrow stress is amplifying the move. The options market registered a small uptick in defensiveness on Wednesday, with the put/call ratio rising to 0.40 against a 20-day average of 0.35, roughly 1.6 standard deviations above the mean. That is elevated but not extreme, and still sits well below the 52-week high of 0.85.
The Street remains broadly constructive but has been trimming targets consistently since the August print. Analysts maintained positive ratings across the board after Q1 results in early August but cut price targets sharply: Keybanc moved from $190 to $170, Stifel from $197 to $160, while Barclays, which carries a neutral-equivalent rating, came down from $140 to $130. Those cuts are now two months old. The consensus mean target is $165, roughly 46% above the current price of $112.68. That gap is wide enough to warrant scrutiny: it suggests either analysts have not fully reset expectations or the stock has de-rated faster than the Street has followed. Valuation has compressed accordingly, with the EV/EBITDA multiple falling to 5.7x and the trailing PE at 12.8x. The EV/EBIT factor score ranks in the 95th percentile of the universe, pointing to an unusually cheap earnings yield relative to peers, though the forward EPS momentum scores are deeply negative at the 11th and 18th percentile over 90-day and 30-day windows respectively, meaning the market is not yet convinced the earnings trajectory warrants re-rating.
The bear case centres on China exposure. Roughly half of Cirrus Logic's revenue comes from the Chinese market, leaving the company directly in the crosshairs of trade tensions that have become a recurring theme for the semiconductor sector. The bull case rests on product diversification into next-generation ADCs, DACs, and automotive haptics, a longer-cycle story that has yet to move the needle materially on near-term numbers. The ORTEX short score of 45.9 is neutral and has drifted slightly lower over the past two weeks, consistent with a stock that is neither under acute short pressure nor attracting strong conviction buying. The sector score sits at the 50th percentile.
Wikipedia attention for Cirrus Logic is running at a z-score of 2.8 against its own 90-day history, a notably elevated retail attention signal as of mid-September. That spike in page views did not translate into price support, which is worth noting. On the institutional side, BlackRock added 415,542 shares in the period to September 30, lifting its stake to 11.3% of shares outstanding. State Street also added 223,924 shares over the same period. No 13D activists are on the register. The Vanguard Group filed a 13G/A in March showing a stake that fell to zero from a prior 12.9%, though Vanguard Capital Management and Vanguard Portfolio Management subsequently filed fresh 13G forms in April disclosing combined positions of roughly 12.7% of shares. Those filings are as of April and stakes may have moved since. EVP of R&D Jeffrey Baumgartner has been selling consistently under a 10b5-1 plan at roughly 1,166 shares per month, with the most recent sale on September 21 at $119. These are scheduled, pre-arranged disposals and carry limited informational weight.
The last earnings print, reported August 5, saw the stock fall 7.5% the next day and 8.8% over the following five sessions. The next report is November 4, now 27 days away. With the stock already 6% lower on the week and analyst targets sitting well above the current price, the question heading into that print is whether the Street's optimism on product diversification starts to find evidence in the numbers, or whether China-related demand uncertainty extends the de-rating.
See the live data behind this article on ORTEX.
Open CRUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
